|
|
Assessment for Soluble Nickel Salts
TERA conducted an
IRIS assessment for soluble nickel salts. The first drafts and initial peer
review of the document were jointly sponsored by U.S. EPA’ s Office of Water,
Health Canada, and the Metal Finishing Association of Southern California (MFASC,
an industry group), as part of TERA's
goal of fostering cooperation between industry and regulatory agencies, and
leveraging scarce government dollars by supplementing them with industry
funding. Cancer and noncancer assessments via the oral and inhalation routes
were conducted. This assessment was unusual in the attention paid to the
importance of the form of nickel (i.e., soluble vs. insoluble compounds) in
determining the cancer risk. To address this question, the assessment included
an in-depth evaluation of the cancer mode of action under EPA’s Draft
Carcinogenicity Assessment Guidelines, and a comparison of the toxicokinetics of
soluble and insoluble nickel compounds. An updated RfD and a RfC were also
derived. In light of the size and complexity of the epidemiology database, TERA
also enlisted the services of an epidemiologist and an industrial hygienist to
evaluate the data. The draft IRIS Toxicological Support Document underwent
external peer review, and has been revised in response to the peer review
comments. Results of the assessment have been presented at scientific meetings.
In order to reach a wider scientific audience, the results of the initial
assessment were also published in a peer-reviewed journal.
To download the document, go here. (Need Adobe Reader to read this PDF file? Click here)
- HABER, L.T., G.L. DIAMOND, G.L. Q. ZHAO, L. ERDREICH and M. L. DOURSON (2000). Hazard identification and dose-response of ingested nickel soluble salts. Reg. Tox. Pharmacol, 31: 231-241.
- HABER, L.T., L. ERDREICH, G.L. DIAMOND, A.M. MAIER, R. RATNEY, Q. ZHAO and M.L. DOURSON (2000). Hazard identification and dose-response of inhaled nickel soluble salts. Reg. Tox. Pharmacol, 31: 210-230.
For more information, contact Dr. Lynne Haber at 513-542-7475, extension 17 or Haber@tera.org.
© 2003 Toxicology Excellence for Risk Assessment
2300 Montana Avenue, Suite 409,
Cincinnati OH 45211
Phone: 513-542-7475
Fax: 513-542-7487
Email: TERA@TERA.org
Last updated: 01/03/2007